Cargando…
Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis
INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512461/ https://www.ncbi.nlm.nih.gov/pubmed/37744517 http://dx.doi.org/10.3389/fpubh.2023.1243408 |
_version_ | 1785108364449021952 |
---|---|
author | Cao, Kexin Wu, Xiaoyue Yang, Mengya Chen, Can Zhang, Xiaobao Jiang, Daixi Du, Yuxia Chen, Mengsha You, Yue Zhou, Wenkai Qi, Jiaxing Chen, Dingmo Yan, Rui Miao, Ziping Yang, Shigui |
author_facet | Cao, Kexin Wu, Xiaoyue Yang, Mengya Chen, Can Zhang, Xiaobao Jiang, Daixi Du, Yuxia Chen, Mengsha You, Yue Zhou, Wenkai Qi, Jiaxing Chen, Dingmo Yan, Rui Miao, Ziping Yang, Shigui |
author_sort | Cao, Kexin |
collection | PubMed |
description | INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk factors. METHODS: We included 208 related studies involving 1,785,569 participants published between 1997 and 2022. Random-effects models were used to pool prevalence, and subgroup analyses were conducted by population, gender, age, study period, regions, and rural–urban distribution. The meta regression models and pooled odds ratios (OR) were performed to identify risk factors for HEV infections. RESULTS: The pooled anti-HEV IgG, IgM, and Ag seroprevalence, and RNA detection rates in China from 1997 to 2022 were 23.17% [95% confidence interval (CI): 20.23–26.25], 0.73% (95% CI: 0.55–0.93), 0.12% (95% CI: 0.01–0.32), and 6.55% (95% CI: 3.46–12.05), respectively. The anti-HEV IgG seropositivity was higher in the occupational population (48.41%; 95% CI: 40.02–56.85) and older adult aged 50–59 years (40.87%; 95% CI: 31.95–50.11). The dominant genotype (GT) of hepatitis E in China was GT4. Notably, drinking non-tap water (OR = 1.82; 95% CI: 1.50–2.20), consumption of raw or undercooked meat (OR = 1.47; 95% CI: 1.17–1.84), and ethnic minorities (OR = 1.50; 95% CI: 1.29–1.73) were risk factors of anti-HEV IgG seroprevalence. DISCUSSIONS: Overall, the prevalence of hepatitis E was relatively high in China, especially among older adults, ethnic minorities, and humans with occupational exposure to pigs. Thus, there is a need for preventive measures, including HEV infection screening and surveillance, health education, and hepatitis E vaccine intervention in high-risk areas and populations. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023397036. |
format | Online Article Text |
id | pubmed-10512461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105124612023-09-22 Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis Cao, Kexin Wu, Xiaoyue Yang, Mengya Chen, Can Zhang, Xiaobao Jiang, Daixi Du, Yuxia Chen, Mengsha You, Yue Zhou, Wenkai Qi, Jiaxing Chen, Dingmo Yan, Rui Miao, Ziping Yang, Shigui Front Public Health Public Health INTRODUCTION: Several studies have reported on hepatitis E virus (HEV) prevalence in various regions of China, but the results vary widely. Herein, we conducted a systematic review and meta-analysis to assess the seroprevalence, RNA-positive rate, genotype distribution of HEV in China, and its risk factors. METHODS: We included 208 related studies involving 1,785,569 participants published between 1997 and 2022. Random-effects models were used to pool prevalence, and subgroup analyses were conducted by population, gender, age, study period, regions, and rural–urban distribution. The meta regression models and pooled odds ratios (OR) were performed to identify risk factors for HEV infections. RESULTS: The pooled anti-HEV IgG, IgM, and Ag seroprevalence, and RNA detection rates in China from 1997 to 2022 were 23.17% [95% confidence interval (CI): 20.23–26.25], 0.73% (95% CI: 0.55–0.93), 0.12% (95% CI: 0.01–0.32), and 6.55% (95% CI: 3.46–12.05), respectively. The anti-HEV IgG seropositivity was higher in the occupational population (48.41%; 95% CI: 40.02–56.85) and older adult aged 50–59 years (40.87%; 95% CI: 31.95–50.11). The dominant genotype (GT) of hepatitis E in China was GT4. Notably, drinking non-tap water (OR = 1.82; 95% CI: 1.50–2.20), consumption of raw or undercooked meat (OR = 1.47; 95% CI: 1.17–1.84), and ethnic minorities (OR = 1.50; 95% CI: 1.29–1.73) were risk factors of anti-HEV IgG seroprevalence. DISCUSSIONS: Overall, the prevalence of hepatitis E was relatively high in China, especially among older adults, ethnic minorities, and humans with occupational exposure to pigs. Thus, there is a need for preventive measures, including HEV infection screening and surveillance, health education, and hepatitis E vaccine intervention in high-risk areas and populations. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023397036. Frontiers Media S.A. 2023-09-07 /pmc/articles/PMC10512461/ /pubmed/37744517 http://dx.doi.org/10.3389/fpubh.2023.1243408 Text en Copyright © 2023 Cao, Wu, Yang, Chen, Zhang, Jiang, Du, Chen, You, Zhou, Qi, Chen, Yan, Miao and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Cao, Kexin Wu, Xiaoyue Yang, Mengya Chen, Can Zhang, Xiaobao Jiang, Daixi Du, Yuxia Chen, Mengsha You, Yue Zhou, Wenkai Qi, Jiaxing Chen, Dingmo Yan, Rui Miao, Ziping Yang, Shigui Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title | Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title_full | Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title_fullStr | Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title_full_unstemmed | Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title_short | Prevalence of hepatitis E virus in China from 1997 to 2022: a systematic review and meta-analysis |
title_sort | prevalence of hepatitis e virus in china from 1997 to 2022: a systematic review and meta-analysis |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512461/ https://www.ncbi.nlm.nih.gov/pubmed/37744517 http://dx.doi.org/10.3389/fpubh.2023.1243408 |
work_keys_str_mv | AT caokexin prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT wuxiaoyue prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT yangmengya prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT chencan prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT zhangxiaobao prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT jiangdaixi prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT duyuxia prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT chenmengsha prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT youyue prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT zhouwenkai prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT qijiaxing prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT chendingmo prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT yanrui prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT miaoziping prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis AT yangshigui prevalenceofhepatitisevirusinchinafrom1997to2022asystematicreviewandmetaanalysis |